Glucagon-like peptide-1 receptor agonists mitigate the risk of major adverse cardiovascular events in patients with atopic dermatitis and type 2 diabetes

Published: 21 July 2025| Version 1 | DOI: 10.17632/8b97vdk8ts.1
Contributor:
Natalie Braun

Description

Supplementary materials for a study examining the impact of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on cardiovascular outcomes in patients with atopic dermatitis.

Files

Institutions

  • Harvard Medical School
  • Massachusetts General Hospital

Categories

Dermatology, Cardiovascular Disease, Type 2 Diabetes, Atopic Dermatitis, Glucagon-Like Peptide-1 Receptor Agonist

Licence